NanoEcho has, as one of seven companies, been chosen to participate cost-free in the Smile Incubator and Medicon Village program “10 X Health.” The program provides expertise in business development and focuses on established Life Science companies transitioning from being a startup to becoming a scale-up.
NanoEcho has been awarded an innovation grant from Vinnova of SEK 99,000 within the scope of business development. The awarded grant is intended to finance a market analysis of potential customer segments.
NanoEcho has been awarded a grant from the SME (Small and Medium Enterprises) -fund within the European Union Intellectual Property Office to cover initial fees related to a new patent application and trademark protection. These grants are provided to support the management of intellectual property assets for European SMEs.
NanoEcho’s method has got its patent approved in the USA. This milestone means that NanoEcho’s technology is now protected in the important US market. The patent protects the design of a hand-held probe, which combines ultrasound transducers and magnets placed on the same device. This patent has already been approved in Europe, Japan, South Korea and Canada.
Images generated with NanoEcho’s system were shown for the first time to internationally leading colorectal surgeons at the annual Swedish conference on colorectal surgery.
NanoEcho strengthens the organization by hiring Ulrika Axelsson as responsible for the company’s clinical operations. Ulrika will be part of the company’s executive management team and will, among other things, be responsible for planning and carrying out the company’s clinical studies, with the goal of getting market approval for NanoEcho’s system for rectal cancer diagnostics.
A new Board that reflects the Company’s development has been appointed. The newly appointed Chairman is Daniel Johnsson, former CEO and founder of, among others, Exertis Nordics, now investor and advisor. A new member of the Company’s Board is PhD and Business Coach Ann-Christin Malmborg Hager.
Yesterday was a historic day for NanoEcho. To our knowledge, this is the first time ever that the magnetomotive ultrasound method has been applied to human tissue. This was carried out on operated cancer tissue using NanoEcho’s first generation portable system at Sahlgrenska University Hospital in Gothenburg. Our system is designed to map, with high precision, the spread of cancer to the lymph nodes, an important marker of how far the cancer has progressed, even before surgery. Our clinical study is now underway at Sahlgrenska University Hospital.
The basic patent for NanoEcho’s method has now been granted in Japan. We have also received positive feedback on the same patent in Europe from the European Patent Office, which has announced that it intends to grant the patent. The same patent is also under review in Canada and the US, where the process is also progressing according to plan.
NanoEcho has been given the go-ahead to begin clinical trials on surgically removed rectal cancer tissue at Sahlgrenska University Hospital in Gothenburg and at Skåne University Hospital in Malmö. The first patient has now been recruited at Sahlgrenska University Hospital. NanoEcho is developing a new medical imaging technique for the diagnosis of rectal cancer. The ambition is to contribute to a more reliable mapping of cancer spread to nearby lymph nodes, which is an important marker of how far along the cancer is.